Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04675333 · ClinicalTrials.gov registry record · Phase 2

Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)

A Phase 2 study of Head and Neck Cancer and Head and Neck Squamous Cell Carcinoma, sponsored by ALX Oncology.

Active
Registry status
Phase 2
Development phase
172
Enrollment target
20
Study locations

NCT04675333: Active Phase 2 study of Head and Neck Cancer and Head and Neck Squamous Cell Carcinoma, sponsored by ALX Oncology.

NCT04675333 is a Phase 2 study of Head and Neck Cancer and Head and Neck Squamous Cell Carcinoma that is active but no longer recruiting, run by ALX Oncology. The registered enrollment target is 172 participants, below the 260-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (34% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04675333, a Phase 2 study of Head and Neck Cancer and Head and Neck Squamous Cell Carcinoma, is active but no longer recruiting, sponsored by ALX Oncology.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
172 participants
Enrollment target
20
Study locations

Study Summary

A Phase 2 Study of evorpacept (ALX148) in Combination With pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma.

Conditions Studied

Head and Neck Cancer Head and Neck Squamous Cell Carcinoma

Interventions

  • DRUG pembrolizumab
  • DRUG evorpacept
  • DRUG Cisplatin/Carboplatin; 5FU

Study Locations (20)

Other

  • Sir Charles Gairdner Hospital - Nedlands
  • Cliniques Universitaires Saint-Luc - Brussels
  • AZ Groeninge - Kortrijk
  • Amsterdam UMC, Locatie VUMC - Amsterdam

California

  • Hoag Hospital - Irvine
  • University of California San Diego - La Jolla
  • Cedar Sinai Medical Center - Los Angeles

Florida

  • University of Miami, Sylvester Comprehensive Cancer Center - Miami
  • Moffitt Cancer Center - Tampa

Illinois

  • Rush University Medical Center - Chicago

Kentucky

  • University of Louisville - Louisville

Maryland

  • University of Maryland Medical System - Baltimore

New York

  • Memorial Sloan Kettering - New York

Ohio

  • The Ohio State University - Columbus

Trial Details

FieldValue
Enrollment Target 172 participants
Start Date 2021-05-10
Est. Completion 2026-06-30
Phase Phase 2
ALX Oncology

9 total trials

What the registry record for NCT04675333 still lists

NCT04675333 is an interventional study that assigns participants to a tested intervention. The registered 172 participants enrollment target is mid-sized for trials with a published cap, below the 260-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (34% lower).

The record links to 2 conditions, with Head and Neck Cancer appearing as the primary indexed condition, and to 3 interventions - of which pembrolizumab is the first listed.

NCT04675333 names 20 study sites across 14 states, led by Other, California, Florida.

Frequently Asked Questions

What is clinical trial NCT04675333 about?

NCT04675333 is a clinical study titled "Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)". A Phase 2 Study of evorpacept (ALX148) in Combination With pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma.

What is the current status of trial NCT04675333?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 172 participants. The study started on 2021-05-10. Estimated completion is 2026-06-30.

What conditions does trial NCT04675333 study?

This clinical trial studies the following conditions: Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma.

What interventions are being tested in trial NCT04675333?

The interventions under investigation include: pembrolizumab (DRUG), evorpacept (DRUG), Cisplatin/Carboplatin; 5FU (DRUG).

Who is sponsoring clinical trial NCT04675333?

This trial is sponsored by ALX Oncology, which has 9 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04675333 being conducted?

This trial has 20 study locations across California, Florida, Illinois, Kentucky, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Head and Neck Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04675333's enrollment target sits among peer trials

172 56th of 250 higher than 195 of 250 other Head and Neck Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Head and Neck Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04801797 · 172 participants · Phase 2

    Venetoclax + Azacitidine vs. Induction Chemotherapy in AML

  • NCT04867317 · 172 participants · Phase 3

    Growth Hormone Replacement Therapy in Veterans With Mild Traumatic Brain Injury (mTBI) and Adult Growth Hormone Deficiency (AGHD)

  • NCT05357040 · 172 participants · Phase 2

    Antidepressant Effects of Nitrous Oxide

  • NCT05587517 · 172 participants · Phase 2

    A Clinical Trial of Interventions to Support Family Surrogates of Critically Ill Patients

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT04675333, the US trial registry maintained by the National Library of Medicine. NCT04675333 (mid enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.